NASDAQ · Biotechnology

RGNX (RGNX) Stock

$10.30 +3.41% NASDAQ: RGNX Healthcare

Valuation

MetricValue
Price$10.30
Market Cap$532.48M
P/E Ratio-1.51
P/B Ratio2.84
P/S Ratio3.35
EPS (TTM)$-3.76
52-Week High$16.19
52-Week Low$5.46
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-188.35%
ROA-42.83%
ROCE-156.31%
Gross Margin-95.29%
Operating Margin-94.71%
Net Margin-3.30%
Debt/Equity3.37
Current Ratio2.38

Annual Financials (USD)

Metric20212022202320242025
Revenue$470.0M$113.0M$90.0M$83.0M$170.0M
Operating Profit$160.0M$-263.0M$-268.0M$-233.0M$-161.0M
Net Profit$128.0M$-280.0M$-263.0M$-227.0M$-194.0M
EPS$2.91$-6.50$-6.02$-4.59$-3.76
Op Margin34.0%-233.2%-297.1%-280.0%-94.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$833.0M$574.0M$466.0M$453.0M
Total Liabilities$350.0M$317.0M$262.0M$206.0M$350.0M
Cash$345.0M$97.0M$35.0M$58.0M$34.0M
Borrowings$87.0M$95.0M$89.0M$82.0M$261.0M

Latest News

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? Zacks · Jul 22, 2026 REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting PR Newswire · Jul 18, 2026 Top Premarket Decliners MT Newswires · Jul 17, 2026 REGENXBIO Prices $100 Million Public Offering MT Newswires · Jul 17, 2026 REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants PR Newswire · Jul 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$219.0M$-207.0M$-218.0M$-173.0M$-124.0M
Investing Cash Flow$-491.0M$-43.0M$181.0M$101.0M$-18.0M
Financing Cash Flow$-23.0M$-31.0M$-42.0M$-38.0M$116.0M
Net Cash Flow$7.0M$-248.0M$-62.0M$23.0M$-23.0M
Free Cash Flow$135.0M$-238.0M$-228.0M$-176.0M$-126.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-80.44%
Quick Ratio2.62
Interest Coverage-3.58
Return 1Y12.76%
Return 3Y-43.21%
Return 5Y-65.83%

Ownership

Insiders Held6.59%
Institutions Held66.91%
Institutions Float Held71.63%
Institutional HolderSharesReport Date
Blackrock Inc.5,782,8082026-03-31
Redmile Group, LLC4,368,8042026-03-31
JPMORGAN CHASE & CO3,483,8002026-03-31
State Street Corporation2,731,4852026-03-31
Morgan Stanley2,066,1572026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABSI $7.13 -5.69% -11.32 $1.21B 0.00%
CRVS $13.31 +3.02% -23.00 $1.12B 0.00%
FDMT $10.09 -0.88% -3.47 $527.47M 0.00%
GOSSGossamer Bio, Inc. $0.19 +38.24% -0.17 $44.10M 0.00%
KALV $27.00 +0.00% -8.28 $1.44B 0.00%

About RGNX

RGNX is led by CEO Curran Simpson, employs 353 people, headquartered in US, publicly traded since 2015.

RGNX stock trades at $10.30 with a market capitalization of $532.48M. The stock is valued at a price-to-earnings (P/E) ratio of -1.51, price-to-book of 2.84, price-to-sales of 3.35. Over the past 52 weeks the stock has ranged between $5.46 and $16.19, and currently trades 36.4% below its 52-week high.

On profitability, RGNX generates a return on equity (ROE) of -188.35%, return on capital employed of -156.31%, an operating margin of -94.71%, a net profit margin of -3.30%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides